Moderna and Merck announced a successful late-stage trial for a personalized mRNA vaccine designed to help prevent the return and spread of melanoma. The vaccine, which utilizes the modified mRNA technology developed by Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research, and Katalin Karikó, PhD, Adjunct Professor, both at Penn Medicine, will also be tested against other cancers. Learn more here and read an interview here with Robert H. Vonderheide, MD, DPhil, Director of the Abramson Cancer Center of the University of Pennsylvania.